Click for full image >>
is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.
TG Therapeutics, Inc. to Host Conference Call on First Quarter 2016 Financial Results and Business Update
TG Therapeutics, Inc. Launches First Clinical Trial in Multiple Sclerosis (MS) for TG-1101 (Ublituximab)
2 Gansevoort Street, 9th Floor, New York NY 10014 - P:212.554.4484 - Email Us
Web Site Development by Tidal Media Group